1osn

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /><applet load="1osn" size="450" color="white" frame="true" align="right" spinBox="true" caption="1osn, resolution 3.20&Aring;" /> '''Crystal structure of...)
Line 1: Line 1:
-
[[Image:1osn.jpg|left|200px]]<br /><applet load="1osn" size="450" color="white" frame="true" align="right" spinBox="true"
+
[[Image:1osn.jpg|left|200px]]<br /><applet load="1osn" size="350" color="white" frame="true" align="right" spinBox="true"
caption="1osn, resolution 3.20&Aring;" />
caption="1osn, resolution 3.20&Aring;" />
'''Crystal structure of Varicella zoster virus thymidine kinase in complex with BVDU-MP and ADP'''<br />
'''Crystal structure of Varicella zoster virus thymidine kinase in complex with BVDU-MP and ADP'''<br />
==Overview==
==Overview==
-
Herpes virus thymidine kinases are responsible for the activation of, nucleoside antiviral drugs including (E)-5-(2-bromovinyl)-2'-deoxyuridine., Such viral thymidine kinases (tk), beside having a broader substrate, specificity compared with host cell enzymes, also show significant, variation in nucleoside phosphorylation among themselves. We have, determined the crystal structure of Varicella zoster virus (VZV, human, herpes virus 3) thymidine kinase complexed with, (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-monophosphate and ADP. Differences, in the conformation of a loop region (residues 55-61) and the position of, two alpha-helices at the subunit interface of VZV-tk compared with the, herpes simplex virus type 1 (human herpes virus 1) enzyme give rise to, changes in the positioning of residues such as tyrosine 66 and glutamine, 90, which hydrogen bond to the substrate in the active site. Such changes, in combination with the substitution in VZV-tk of two phenylalanine, residues (in place of a tyrosine and methionine), which sandwich the, substrate pyrimidine ring, cause an alteration in the positioning of the, base. The interaction of the (E)-5-(2-bromovinyl)-2'-deoxyuridine, deoxyribose ring with the protein is altered by substitution of tyrosine, 21 and phenylalanine 139 (analagous to herpes simplex virus type 1, histidine 58 and tyrosine 172), which may explain some of the differences, in nucleoside sugar selectivity between both enzymes. The altered active, site architecture may also account for the differences in the substrate, activity of ganciclovir for the two thymidine kinases. These data should, be of use in the design of novel antiherpes and antitumor drugs.
+
Herpes virus thymidine kinases are responsible for the activation of nucleoside antiviral drugs including (E)-5-(2-bromovinyl)-2'-deoxyuridine. Such viral thymidine kinases (tk), beside having a broader substrate specificity compared with host cell enzymes, also show significant variation in nucleoside phosphorylation among themselves. We have determined the crystal structure of Varicella zoster virus (VZV, human herpes virus 3) thymidine kinase complexed with (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-monophosphate and ADP. Differences in the conformation of a loop region (residues 55-61) and the position of two alpha-helices at the subunit interface of VZV-tk compared with the herpes simplex virus type 1 (human herpes virus 1) enzyme give rise to changes in the positioning of residues such as tyrosine 66 and glutamine 90, which hydrogen bond to the substrate in the active site. Such changes in combination with the substitution in VZV-tk of two phenylalanine residues (in place of a tyrosine and methionine), which sandwich the substrate pyrimidine ring, cause an alteration in the positioning of the base. The interaction of the (E)-5-(2-bromovinyl)-2'-deoxyuridine deoxyribose ring with the protein is altered by substitution of tyrosine 21 and phenylalanine 139 (analagous to herpes simplex virus type 1 histidine 58 and tyrosine 172), which may explain some of the differences in nucleoside sugar selectivity between both enzymes. The altered active site architecture may also account for the differences in the substrate activity of ganciclovir for the two thymidine kinases. These data should be of use in the design of novel antiherpes and antitumor drugs.
==About this Structure==
==About this Structure==
-
1OSN is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_herpesvirus_3 Human herpesvirus 3] with ADP and BVP as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Thymidine_kinase Thymidine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.21 2.7.1.21] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1OSN OCA].
+
1OSN is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Human_herpesvirus_3 Human herpesvirus 3] with <scene name='pdbligand=ADP:'>ADP</scene> and <scene name='pdbligand=BVP:'>BVP</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Thymidine_kinase Thymidine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.21 2.7.1.21] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1OSN OCA].
==Reference==
==Reference==
Line 15: Line 15:
[[Category: Thymidine kinase]]
[[Category: Thymidine kinase]]
[[Category: Balzarini, J.]]
[[Category: Balzarini, J.]]
-
[[Category: Bird, L.E.]]
+
[[Category: Bird, L E.]]
[[Category: Degreve, B.]]
[[Category: Degreve, B.]]
-
[[Category: Leslie, K.D.]]
+
[[Category: Leslie, K D.]]
[[Category: Ren, J.]]
[[Category: Ren, J.]]
-
[[Category: Stammers, D.K.]]
+
[[Category: Stammers, D K.]]
[[Category: Wright, A.]]
[[Category: Wright, A.]]
[[Category: ADP]]
[[Category: ADP]]
Line 28: Line 28:
[[Category: thymidine kinase]]
[[Category: thymidine kinase]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Nov 20 23:09:41 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:21:08 2008''

Revision as of 12:21, 21 February 2008


1osn, resolution 3.20Å

Drag the structure with the mouse to rotate

Crystal structure of Varicella zoster virus thymidine kinase in complex with BVDU-MP and ADP

Overview

Herpes virus thymidine kinases are responsible for the activation of nucleoside antiviral drugs including (E)-5-(2-bromovinyl)-2'-deoxyuridine. Such viral thymidine kinases (tk), beside having a broader substrate specificity compared with host cell enzymes, also show significant variation in nucleoside phosphorylation among themselves. We have determined the crystal structure of Varicella zoster virus (VZV, human herpes virus 3) thymidine kinase complexed with (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-monophosphate and ADP. Differences in the conformation of a loop region (residues 55-61) and the position of two alpha-helices at the subunit interface of VZV-tk compared with the herpes simplex virus type 1 (human herpes virus 1) enzyme give rise to changes in the positioning of residues such as tyrosine 66 and glutamine 90, which hydrogen bond to the substrate in the active site. Such changes in combination with the substitution in VZV-tk of two phenylalanine residues (in place of a tyrosine and methionine), which sandwich the substrate pyrimidine ring, cause an alteration in the positioning of the base. The interaction of the (E)-5-(2-bromovinyl)-2'-deoxyuridine deoxyribose ring with the protein is altered by substitution of tyrosine 21 and phenylalanine 139 (analagous to herpes simplex virus type 1 histidine 58 and tyrosine 172), which may explain some of the differences in nucleoside sugar selectivity between both enzymes. The altered active site architecture may also account for the differences in the substrate activity of ganciclovir for the two thymidine kinases. These data should be of use in the design of novel antiherpes and antitumor drugs.

About this Structure

1OSN is a Single protein structure of sequence from Human herpesvirus 3 with and as ligands. Active as Thymidine kinase, with EC number 2.7.1.21 Full crystallographic information is available from OCA.

Reference

Crystal structure of varicella zoster virus thymidine kinase., Bird LE, Ren J, Wright A, Leslie KD, Degreve B, Balzarini J, Stammers DK, J Biol Chem. 2003 Jul 4;278(27):24680-7. Epub 2003 Apr 9. PMID:12686543

Page seeded by OCA on Thu Feb 21 14:21:08 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools